An exciting future for Biovotion as part of Biofourmis

The Biovotion team is excited to announce the acquisition of Biovotion AG by Biofourmis. Biofourmis is a fast-growing global leader in digital therapeutics based in Boston, Mass., United States. The two companies have been working together over the past few years and have leveraged each other’s technologies across numerous clinical, commercial and research applications.

With this step to bring the companies’ technologies and assets together, Biofourmis will now offer Biovotion’s clinical-grade wearable Everion® as part of its Biovitals™ ecosystem, which also includes the Biovitals™ Analytics Engine for predictive analytics of more than 20 clinical and non-clinical parameters collected from the Everion® wearable.

High-quality clinical grade physiological data from wearables are becoming integral across all areas of healthcare, offering continuous real-time physiologic data formerly only available in clinical settings. Combining Biovotion’s cutting-edge wearables with Biofourmis’ digital therapeutics platform and its leading artificial intelligence (AI)-driven predictive analytics creates the most comprehensive digital therapeutics solution on the market.

A Complete, Integrated Solution
Biofourmis’ clinically validated and FDA-approved software-based digital therapeutics, part of the growing Biovitals™ ecosystem, are already leveraged across multiple segments of healthcare and life sciences to predict and prevent adverse health events and provide better outcomes for patients. The multi-parameter physiology data captured from Everion® will be an integral component of the Biovitals® digital therapeutics pipeline, which manages conditions such as heart failure, COPD, oncology and pain and delivers personalized care; demonstrates the value of and potentially complement pharmacotherapy; provides cost-effective solutions for payers; and advances clinical research.

Leveraging Synergies
The entire Biovotion team will be incorporated into the Biofourmis family under the name “Biofourmis AG” in Zürich. We are looking forward to bringing our customers even more robust and synergistic technologies and solutions under the Biofourmis mantle. This agreement provides huge benefits for our customers, including providers, payers, managed care organizations and pharmaceutical companies. Ultimately, we look forward to reaching more patients across the globe to help them achieve optimal health outcomes.

For more information on Biofourmis visit:
If you want to learn more about the acquisition, please see the Nov. 18 press release here.

Please feel free to contact us with any questions at: